Cargando…

Natural killer cells and immune-checkpoint inhibitor therapy: Current knowledge and new challenges

The discovery of immune checkpoints (ICs) and the development of specific blockers to relieve immune effector cells from this inhibiting mechanism has changed the view of anti-cancer therapy. In addition to cytotoxic T lymphocyte antigen 4 (CTLA4) and programmed death 1 (PD1), classical ICs of T lym...

Descripción completa

Detalles Bibliográficos
Autores principales:	Poggi, Alessandro, Zocchi, Maria Raffaella
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society of Gene & Cell Therapy 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8693432/ https://www.ncbi.nlm.nih.gov/pubmed/34977340 http://dx.doi.org/10.1016/j.omto.2021.11.016

Ejemplares similares

Antigen Presenting Cells and Stromal Cells Trigger Human Natural Killer Lymphocytes to Autoreactivity: Evidence for the Involvement of Natural Cytotoxicity Receptors (NCR) and NKG2D
por: Poggi, Alessandro, et al.
Publicado: (2006)

Immune Checkpoint Receptor/Ligand Expression and Chemotherapy in Colorectal Cancer
por: Benelli, Roberto, et al.
Publicado: (2023)

Checkpoint Inhibitors and Engineered Cells: New Weapons for Natural Killer Cell Arsenal Against Hematological Malignancies
por: Giuliani, Massimo, et al.
Publicado: (2020)

Selective Role of Mevalonate Pathway in Regulating Perforin but Not FasL and TNFalpha Release in Human Natural Killer Cells
por: Poggi, Alessandro, et al.
Publicado: (2013)

Human Gut-Associated Natural Killer Cells in Health and Disease
por: Poggi, Alessandro, et al.
Publicado: (2019)

Imatinib mesylate can help to direct natural immunity toward an anti-leukemic reactivity by acting on the bone marrow microenvironment
por: Poggi, Alessandro, et al.
Publicado: (2012)

γδ T Lymphocytes as a First Line of Immune Defense: Old and New Ways of Antigen Recognition and Implications for Cancer Immunotherapy
por: Poggi, Alessandro, et al.
Publicado: (2014)

How to exploit stress-related immunity against Hodgkin’s lymphoma: Targeting ERp5 and ADAM sheddases
por: Poggi, Alessandro, et al.
Publicado: (2013)

Three-Dimensional (3D) Culture Models in Cancer Investigation, Drug Testing and Immune Response Evaluation
por: Benelli, Roberto, et al.
Publicado: (2020)

HIV-1 Tat Triggers TGF-β Production and NK Cell Apoptosis that is Prevented by Pertussis Toxin B
por: Poggi, Alessandro, et al.
Publicado: (2006)

NK Cell Autoreactivity and Autoimmune Diseases
por: Poggi, Alessandro, et al.
Publicado: (2014)

Immune checkpoint inhibitor induced nephrotoxicity: An ongoing challenge
por: Catalano, Martina, et al.
Publicado: (2022)

Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: Current Progresses and Challenges
por: Liu, Hao-Tian, et al.
Publicado: (2021)

Angiogenesis and immune checkpoint inhibitors as therapies for hepatocellular carcinoma: current knowledge and future research directions
por: Hilmi, Marc, et al.
Publicado: (2019)

Targeting the Epidermal Growth Factor Receptor Can Counteract the Inhibition of Natural Killer Cell Function Exerted by Colorectal Tumor-Associated Fibroblasts
por: Costa, Delfina, et al.
Publicado: (2018)

Current State of Knowledge on the Immune Checkpoint Inhibitors in Triple-Negative Breast Cancer Treatment: Approaches, Efficacy, and Challenges
por: Uchimiak, Katarzyna, et al.
Publicado: (2022)

Imatinib Treatment Induces CD5+ B Lymphocytes and IgM Natural Antibodies with Anti-Leukemic Reactivity in Patients with Chronic Myelogenous Leukemia
por: Catellani, Silvia, et al.
Publicado: (2011)

Sphingomyelin is a prospective metabolic immune checkpoint for natural killer cells
por: Ma, Hongdi, et al.
Publicado: (2023)

Cardiotoxicity associated with immune checkpoint inhibitors: Current status and future challenges
por: Gan, Lu, et al.
Publicado: (2022)

Current Advances in Immunotherapy for Acute Leukemia: An Overview of Antibody, Chimeric Antigen Receptor, Immune Checkpoint, and Natural Killer
por: Shang, Yufeng, et al.
Publicado: (2019)

Immune Checkpoint Blockade: A Strategy to Unleash the Potential of Natural Killer Cells in the Anti-Cancer Therapy
por: Grottoli, Melania, et al.
Publicado: (2022)

How to Hit Mesenchymal Stromal Cells and Make the Tumor Microenvironment Immunostimulant Rather Than Immunosuppressive
por: Poggi, Alessandro, et al.
Publicado: (2018)

Corrigendum: How to Hit Mesenchymal Stromal Cells and Make the Tumor Microenvironment Immunostimulant Rather Than Immunosuppressive
por: Poggi, Alessandro, et al.
Publicado: (2018)

Zoledronate Triggers Vδ2 T Cells to Destroy and Kill Spheroids of Colon Carcinoma: Quantitative Image Analysis of Three-Dimensional Cultures
por: Varesano, Serena, et al.
Publicado: (2018)

Corrigendum: Zoledronate Triggers Vδ2 T Cells to Destroy and Kill Spheroids of Colon Carcinoma: Quantitative Image Analysis of Three-Dimensional Cultures
por: Varesano, Serena, et al.
Publicado: (2018)

Evolution of 3D Cultures: Toward Tailored Preclinical Models
por: Benelli, Roberto, et al.
Publicado: (2023)

Current Landscape of Immune Checkpoint Inhibitor Therapy for Hepatocellular Carcinoma
por: Machairas, Nikolaos, et al.
Publicado: (2022)

Current Landscape of Immune Checkpoint Inhibitor Therapy for Hepatocellular Carcinoma
por: Ruff, Samantha M., et al.
Publicado: (2023)

Identification of druggable inhibitory immune checkpoints on Natural Killer cells in COVID-19
por: Demaria, Olivier, et al.
Publicado: (2020)

Immune checkpoint molecules in natural killer cells as potential targets for cancer immunotherapy
por: Cao, Yuqing, et al.
Publicado: (2020)

TIPE2 is a checkpoint of natural killer cell maturation and antitumor immunity
por: Bi, Jiacheng, et al.
Publicado: (2021)

Inhibitory Receptors and Immune Checkpoints Regulating Natural Killer Cell Responses to Cancer
por: Buckle, Irina, et al.
Publicado: (2021)

Mesenchymal stromal cells as regulators of anti-tumour immune response
por: Poggi, Alessandro, et al.
Publicado: (2015)

Revising the Landscape of Cytokine-Induced Killer Cell Therapy in Lung Cancer: Focus on Immune Checkpoint Inhibitors
por: Vaseq, Rohulla, et al.
Publicado: (2023)

Overcoming Resistance to Checkpoint Inhibitors: Natural Killer Cells in Non-Small Cell Lung Cancer
por: Gemelli, Maria, et al.
Publicado: (2022)

Current Insights into Combination Therapies with MAPK Inhibitors and Immune Checkpoint Blockade
por: Shin, Min Hwa, et al.
Publicado: (2020)

Immune Checkpoint Inhibitors for Vaccine Improvements: Current Status and New Approaches
por: Batista-Duharte, Alexander, et al.
Publicado: (2022)

Cancer Nanomedicine Special Issue Review Anticancer Drug Delivery with Nanoparticles: Extracellular Vesicles or Synthetic Nanobeads as Therapeutic Tools for Conventional Treatment or Immunotherapy
por: Zocchi, Maria Raffaella, et al.
Publicado: (2020)

ADAM10 Site-Dependent Biology: Keeping Control of a Pervasive Protease
por: Tosetti, Francesca, et al.
Publicado: (2021)

Immune checkpoint inhibitors in lymphoma: challenges and opportunities
por: Hatic, Haris, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_1no50q2s86b668h3dpfub6pouh